9310 Athena Circles
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com and follow us on Twitter @IncResilience
6 articles with Resilience
According to recent BioSpace research, diversity and inclusion is an important factor when considering a new employment opportunity for 85% of life sciences community members.
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit
National Resilience, Inc. today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.
National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing cell-free protein synthesis (CFPS) technology.
Resilience Joins Forces with Childen’s Hospital of Philadelpia to Develop Next-Generation Biomanufacturing Technologies, Create Impactful Therapies
National Resilience, Inc. announced a strategic collaboration with Children’s Hospital of Philadelphia ( CHOP ) to implement next-generation biomanufacturing technologies and capabilities aimed at accelerating the creation of impactful therapies and technologies for the benefit of patients.
National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness
National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced that the Government of Canada will invest CAD 199.2 million ($163.8 million), through the Strategic Innovation Fund , in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.